Results from a retrospective multicenter study suggest that continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.
Surgical palliation in patients treated for malignant gastric outlet obstruction maintains quality of life and improves solid food intake for at least 3 months after surgery.
A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.
The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.
Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.
It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.
Regional Cancer Care Associates has continued its expansion along the East Coast by adding 2 Connecticut-based cancer centers with 6 cancer specialists to its network of independent practices.
The Community Oncology Alliance got most of its 2016 Christmas list. CVS Caremark dropped its plan to cut physician-owned dispensaries out of Medicare Part D oral drug distribution, CMS eased off the gas pedal on the Medicare Access and CHIP Reauthorization Act, and the Medicare Part B Drug Payment Model has been discontinued for now.
The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.